GlassScriptPhysician profile
David M Shore
NPI 1184823163
$3,461.11
in general payments reported to CMS, 2019-2025
32 companies · $192 in 2025
The $192 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $878 · 2020: $242 · 2021: $567 · 2022: $325 · 2023: $263 · 2024: $995 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $750 · Food and Beverage: $699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $750.00 |
| Food and Beverage | $699.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $951.93 | 2019-2024 | |
| Medivators INC. | $500.00 | 2021 | |
| Janssen Biotech, INC. | $223.45 | 2019-2023 | Erleada |
| Abbvie INC. | $215.16 | 2024-2025 | |
| Olympus America INC. | $210.21 | 2019-2025 | Itind System, Soltive |
| Astellas Pharma US INC | $180.08 | 2019-2022 | |
| Medtronic Vascular, INC. | $129.13 | 2019 | |
| Verity Pharmaceuticals INC. | $111.49 | 2022-2024 | Trelstar |
| Blue Earth Diagnostics | $105.86 | 2019-2024 | |
| Dendreon Pharmaceuticals LLC | $104.42 | 2019-2023 | Provenge |
| Tolmar Pharmaceuticals, INC. | $79.83 | 2019-2020 | |
| C. R. Bard, INC. & Subsidiaries | $66.73 | 2020 | |
| Sumitomo Pharma America, INC. | $66.46 | 2023 | Gemtesa |
| Laborie Medical Technologies Corp. | $45.42 | 2022 | |
| Coloplast Corp | $42.77 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $37.58 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $37.01 | 2019-2020 | |
| Neotract INC. | $34.88 | 2019-2020 | |
| Amgen INC. | $32.30 | 2019 | |
| Urovant Sciences INC | $32.09 | 2022 | |
| Metuchen Pharmaceuticals | $27.08 | 2019 | |
| Boston Scientific Corporation | $25.46 | 2022 | |
| Terumo Medical Corporation | $22.89 | 2019 | |
| Antares Pharma, INC. | $22.74 | 2022 | |
| Dentsply Ih INC. | $22.69 | 2020 | |
| Smith+Nephew, INC. | $21.87 | 2019 | |
| Accord Healthcare, INC. | $21.15 | 2022 | |
| Calyxo, INC. | $21.05 | 2025 | Cvac Aspiration System |
| Agiliti Surgical, INC. | $20.74 | 2023 | Soltive |
| Hollister Incorporated | $20.03 | 2022 | |
| Pfizer INC. | $14.63 | 2019 | |
| Merck Sharp & Dohme LLC | $13.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Shore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.